HER2 gene amplification in primary mucinous ovarian cancer: a potential therapeutic target.

摘要

Sir: New cancer therapies can be directed at specific signalling pathways of tumour cells. Trastuzumab (Herceptin), a humanized monoclonal antibody that binds selectively to the HER2 protein, is currently being used in breast and some other types of tumours. The purpose of this study was to investigate whether HER2 could be a potential therapeutic target for the treatment of primary mucinous and non-mucinous epithelial ovarian cancer (EOC).Twenty-seven epithelial ovarian cancers, four mucinous and 23 non-mucinous, were analysed in a tissue microarray (TMA) study.